Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2017 Filed Jan 3, 2018 22:39 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 343,053 | $0.00 Strike: $36.22 | $0.00 |
DisclosureSEC source: 0001225208-18-000423 · doc4.xml · derivative · entry 5 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,053 Underlying: Common Stock · 343,053 shares Expires 2022-12-29 F4 · derivative.exercise_date: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through the third anniversary of the grant date (December 29, 2020) and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022). F4 · derivative.expiration_date: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through the third anniversary of the grant date (December 29, 2020) and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022). Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:39 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $36.22 | $398.42 |
DisclosureSEC source: 0001225208-18-000423 · doc4.xml · derivative · entry 4 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,966 Underlying: Common Stock · 11 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:39 UTC |
YOUNG JOHN DGroup President
|
GrantCommon Stock | 55,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000423 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,700 F1 · shares: The reported transaction constitutes the grant of restricted stock units which will vest one third on each of the second, third and fourth anniversaries of grant provided he is continuously employed by Pfizer through the respective anniversaries. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 23:17 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 6,750 | $37.00 | $249,750.00 |
DisclosureSEC source: 0001225208-17-018819 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,458 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2016. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 23:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $37.20 | $148.80 |
DisclosureSEC source: 0001225208-17-018820 · doc4.xml · derivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 23:17 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 8,000 | $37.07 | $296,560.00 |
DisclosureSEC source: 0001225208-17-018820 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,963 Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 23:17 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 20 | $37.20 | $744.00 |
DisclosureSEC source: 0001225208-17-018821 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,990 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 23:17 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $37.20 | $409.20 |
DisclosureSEC source: 0001225208-17-018822 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,954 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 23:17 UTC |
READ IAN CDirector · Chairman & CEO
|
GiftCommon Stock | 7,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018823 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 22:11 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018520 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,136 Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 20:17 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 20 | $36.26 | $725.20 |
DisclosureSEC source: 0001225208-17-017968 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,971 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 20:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $36.26 | $145.04 |
DisclosureSEC source: 0001225208-17-017969 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,316 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 20:17 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $36.26 | $398.86 |
DisclosureSEC source: 0001225208-17-017970 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 21:59 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 21 | $35.36 | $742.56 |
DisclosureSEC source: 0001225208-17-017411 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,955 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 21:59 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $35.36 | $141.44 |
DisclosureSEC source: 0001225208-17-017412 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,314 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 21:59 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $35.36 | $388.96 |
DisclosureSEC source: 0001225208-17-017413 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,936 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 23:03 UTC |
YOUNG JOHN DGroup President
|
GiftCommon Stock | 4,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016837 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,257 Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 23:03 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 7,350 | $34.94 | $256,809.00 |
DisclosureSEC source: 0001225208-17-016838 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,082 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2016. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 23:03 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $35.06 | $385.66 |
DisclosureSEC source: 0001225208-17-016837 · doc4.xml · derivative · entry 4 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,846 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 23:03 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 21 | $35.06 | $736.26 |
DisclosureSEC source: 0001225208-17-016839 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,837 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 23:03 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $35.06 | $140.24 |
DisclosureSEC source: 0001225208-17-016840 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,272 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 21:26 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 20 | $36.34 | $726.80 |
DisclosureSEC source: 0001225208-17-016285 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,815 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 21:26 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $36.34 | $145.36 |
DisclosureSEC source: 0001225208-17-016286 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,267 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 21:26 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $36.34 | $399.74 |
DisclosureSEC source: 0001225208-17-016287 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,834 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:22 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 36 | $36.40 | $1,310.40 |
DisclosureSEC source: 0001225208-17-016231 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,794 Underlying: Common Stock · 36 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:22 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 18 | $36.40 | $655.20 |
DisclosureSEC source: 0001225208-17-016232 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,263 Underlying: Common Stock · 18 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:22 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 36 | $36.40 | $1,310.40 |
DisclosureSEC source: 0001225208-17-016233 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,823 Underlying: Common Stock · 36 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 02, 2017 Filed Nov 2, 2017 23:03 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 7,350 | $35.65 | $262,027.50 |
DisclosureSEC source: 0001225208-17-016838 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,432 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2016. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 14:03 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 962.885 | $35.70 | $34,374.99 |
DisclosureSEC source: 0001225208-17-015663 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,602.617 Underlying: Common Stock · 962.885 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 14:03 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 962.885 | $35.70 | $34,374.99 |
DisclosureSEC source: 0001225208-17-015664 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,005.621 Underlying: Common Stock · 962.885 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 14:03 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 962.885 | $35.70 | $34,374.99 |
DisclosureSEC source: 0001225208-17-015665 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,346.779 Underlying: Common Stock · 962.885 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 14:03 UTC |
SANGER STEPHEN WDirector
|
GrantPhantom Stock Units · Derivative | 1,137.955 | $35.70 | $40,624.99 |
DisclosureSEC source: 0001225208-17-015666 · doc4.xml · derivative · entry 1 SANGER STEPHEN W · CIK 0001204994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,041.582 Underlying: Common Stock · 1,137.955 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 14:03 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 1,137.955 | $35.70 | $40,624.99 |
DisclosureSEC source: 0001225208-17-015667 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,183.319 Underlying: Common Stock · 1,137.955 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 21:39 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 21 | $35.70 | $749.70 |
DisclosureSEC source: 0001225208-17-015840 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,759 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 21:39 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $35.70 | $142.80 |
DisclosureSEC source: 0001225208-17-015841 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,246 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 21:39 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $35.70 | $392.70 |
DisclosureSEC source: 0001225208-17-015842 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,787 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 22:40 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 21 | $35.36 | $742.56 |
DisclosureSEC source: 0001225208-17-015098 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,739 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 22:40 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 11 | $35.36 | $388.96 |
DisclosureSEC source: 0001225208-17-015100 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,777 Underlying: Common Stock · 11 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 22:40 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $35.36 | $141.44 |
DisclosureSEC source: 0001225208-17-015099 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,242 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 22:40 UTC |
HILL CHARLES HExecutive Vice President
|
OtherPhantom Stock Units SSP · Derivative | 14,140 | $35.36 | $499,990.40 |
DisclosureSEC source: 0001225208-17-015101 · doc4.xml · derivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,131 Underlying: Common Stock · 14,140 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.underlying_shares: This transaction constitutes an intra-plan transfer involving the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 13:13 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 30,553 | $35.00 | $1,069,355.00 |
DisclosureSEC source: 0001225208-17-014989 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,096 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2016. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 13:13 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 7,677 | $35.00 | $268,695.00 |
DisclosureSEC source: 0001225208-17-014989 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,649 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2016. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:15 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 7,350 | $34.00 | $249,900.00 |
DisclosureSEC source: 0001225208-17-014619 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,774 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2016. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:37 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 141,193 | $34.00 | $4,800,562.00 |
DisclosureSEC source: 0001225208-17-014480 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 80,762 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:37 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 55,975 | $34.00 | $1,903,150.00 |
DisclosureSEC source: 0001225208-17-014480 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,318 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:37 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 7,350 | $34.00 | $249,900.00 |
DisclosureSEC source: 0001225208-17-014481 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,124 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2016. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:38 UTC |
BOURLA ALBERTGroup President
|
GrantPhantom Stock Units SSP · Derivative | 22 | $33.92 | $746.24 |
DisclosureSEC source: 0001225208-17-014483 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,720 Underlying: Common Stock · 22 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:37 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 94,409 | $34.00 | $3,209,906.00 |
DisclosureSEC source: 0001225208-17-014482 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,389 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:38 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 12 | $33.92 | $407.04 |
DisclosureSEC source: 0001225208-17-014485 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,767 Underlying: Common Stock · 12 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 22:38 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $33.92 | $135.68 |
DisclosureSEC source: 0001225208-17-014484 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,239 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.